CAR-T cells targeting fibroblast activation protein eliminate pathological fibroblasts and preserve cardiac function in a Duchenne Muscular Dystrophy murine model
Authors:
- Céline MarignyCMCéline Marigny
- Gaëlle RevetGRGaëlle Revet
- Anne BergerABAnne Berger
- Morgane BoulchMBMorgane Boulch
- Nathalie MougenotNMNathalie Mougenot
- Zhenlin LiZLZhenlin Li
- Béatrice CorreBCBéatrice Corre
- Mégane LemaitreMLMégane Lemaitre
- Axelle BoisABAxelle Bois
- Clara CastelliCCClara Castelli
- Ara ParlakianAPAra Parlakian
Open Access
- 30 April 2026
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Abstract
Background: Chimeric Antigen Receptor (CAR)-T cells therapy has revolutionized the treatment of hematological cancers and are currently redirected towards non-malignant diseases. If correction of the gene defect remains the cornerstone of the treatment of Duchenne Muscular Dystrophy (DMD), the disease-associated fibrosis can limit its efficacy. We thus assessed the effects of eliminating cardiac fibrosis of DMD by CAR-T cells targeting Fibroblast Activation Protein (FAP), a protein strongly expressed by activated fibroblasts. Methods: In vitro CAR-T cells expressing both FAP and a green fluorescent probe (GFP) were first co-cultured with FAP + of FAP- target cells to check for FAP-expressing lymphocyte activation. Then, anti-FAP CAR-T cells were intravenously delivered in a dystrophic murine model (D2. mdx ), following lymphodepletion, to investigate the kinetics, biodistribution, cardiac functional and anti-fibrotic effects of anti-FAP CAR-T cells compared with control lymphocytes engineered to only express GFP. The mechanism of action at a cellular level was assessed by single-cell RNA-sequencing of harvested hearts. Results: In vitro anti-FAP CAR-T cells were successfully activated when co-cultured with FAP + target cells. In a dystrophic murine model (D2. mdx ), anti-FAP CAR-T cells, intravenously delivered following lymphodepletion, homed to the heart and skeletal muscles, where they decreased FAP and fibrosis-associated genes. Single-cell RNA-sequencing linked these changes to a decrease in a definite cluster of fibrogenic fibroblasts. Concomitantly, anti-FAP CAR-T cells improved cardiac function compared to control mice injected with GFP-transduced T lymphocytes or bovine serum albumin used as negative controls. Conclusions: These results suggest that anti-FAP CAR-T cells could be efficient for mitigating fibrosis and thus complement gene therapy of DMD. More generally, their therapeutic benefits pave the way for potential applications extending to other fibrosis-associated diseases.Keywords
Funding Information
- Labex REVIVE (ANR-10-LABX-73)
- Agence Nationale de la Recherche (ANR-23-CPJ1-0134-01)
- Deutsche Forschungsgemeinschaft (453989101)
- Sorbonne Université
- CNRS
- Institut National de la Santé et de la Recherche Médicale
This publication has 43 references indexed in Scilit:
- Improved AAV9-based gene therapy design for SURF1-related Leigh syndrome with minimal toxicityMolecular Therapy - Methods & Clinical Development, 2025
- FAP-CAR-T cells reduce dystrophic muscle fibrosis, improving adeno-associated virus gene transfer efficacyMolecular Therapy - Methods & Clinical Development, 2025
- Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profileNature Communications, 2025
- CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearnNature Reviews Clinical Oncology, 2023
- Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapyDrug Delivery and Translational Research, 2023
- Early-Onset Late Gadolinium Enhancement is a Prognostic Factor for Duchenne CardiomyopathyPediatric Cardiology, 2022
- Duchenne muscular dystrophyNature Reviews Disease Primers, 2021
- Nerolidol attenuates cyclophosphamide-induced cardiac inflammation, apoptosis and fibrosis in Swiss Albino miceEuropean Journal of Pharmacology, 2019
- Genetic lineage tracing defines myofibroblast origin and function in the injured heartNature Communications, 2016
- PlGF–MMP-9–expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscleNature Medicine, 2008